Cover Image

Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease

Cholinesterase inhibitors constitute one of the mainstays of treatment of Alzheimer disease (AD). Gastrointestinal side effects, difficulty accessing therapeutic doses and poor patient compliance have been identified as barriers to effective treatment with these substances. The rivastigmine transder...

Full description

Saved in:
Bibliographic Details
Main Authors: Emre, Murat (Author) , Bernabei, Roberto (Author) , Blesa, Rafael (Author) , Bullock, Roger (Author) , Cunha, Luis (Author) , Daniëls, Hugo (Author) , Dziadulewicz, Edward (Author) , Förstl, Hans (Author) , Frölich, Lutz (Author) , Gabryelewicz, Tomasz (Author) , Levin, Oleg (Author) , Lindesay, James (Author) , Martínez-Lage, Pablo (Author) , Monsch, Andreas (Author) , Tsolaki, Magda (Author) , Van Laar, Teus (Author)
Format: Article (Journal)
Language:English
Published: 1 July 2010
In: CNS neuroscience & therapeutics
Year: 2010, Volume: 16, Issue: 4, Pages: 246-253
ISSN:1755-5949
DOI:10.1111/j.1755-5949.2010.00141.x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/j.1755-5949.2010.00141.x
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1755-5949.2010.00141.x
Get full text
Author Notes:Murat Emre, Roberto Bernabei, Rafael Blesa, Roger Bullock, Luis Cunha, Hugo Daniëls, Edward Dziadulewicz, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, Oleg Levin, James Lindesay, Pablo Martínez-Lage, Andreas Monsch, Magda Tsolaki & Teus Van Laar
Description
Summary:Cholinesterase inhibitors constitute one of the mainstays of treatment of Alzheimer disease (AD). Gastrointestinal side effects, difficulty accessing therapeutic doses and poor patient compliance have been identified as barriers to effective treatment with these substances. The rivastigmine transdermal patch provides continuous delivery of drug through the skin into the bloodstream, avoiding the fluctuations in plasma concentration associated with oral administration. This pharmacokinetic profile is associated with reduced side effects, resulting in easier access to expected target doses. These benefits, along with other practical advantages of the transdermal patch, may contribute to enhanced patient compliance. Here, we present a review of the current literature on rivastigmine patch, and offer advice based on our own collective clinical experience. Rivastigmine patch provides an efficient option for managing patients with AD, to be considered among the first line therapies for the disease.
Item Description:Gesehen am 22.05.2023
Physical Description:Online Resource
ISSN:1755-5949
DOI:10.1111/j.1755-5949.2010.00141.x

Similar Items